Share on StockTwits
 

Johnson & Johnson (NYSE:JNJ) was upgraded by investment analysts at Ned Davis Research from a “neutral” rating to a “buy” rating in a note issued to investors on Monday, Stock Ratings Network reports.

A number of other firms have also recently commented on JNJ. Analysts at Barclays downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating in a research note to investors on Friday. They now have a $99.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Johnson & Johnson in a research note to investors on Thursday. They now have a $99.00 price target on the stock. Finally, analysts at Citigroup Inc. upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating in a research note to investors on Thursday. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $81.53.

Johnson & Johnson (NYSE:JNJ) traded up 0.01% on Monday, hitting $94.75. The stock had a trading volume of 1,746,319 shares. Johnson & Johnson has a 52-week low of $72.00 and a 52-week high of $95.99. The stock has a 50-day moving average of $93.15 and a 200-day moving average of $90.84. The company has a market cap of $267.3 billion and a P/E ratio of 21.13.

The company also recently announced a quarterly dividend, which is scheduled for Tuesday, March 11th. Investors of record on Tuesday, February 25th will be paid a dividend of 0.66 per share. This represents a $2.64 annualized dividend and a dividend yield of 2.79%. The ex-dividend date is Friday, February 21st.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.